IRRITATION-REDUCING OCULAR IONTOPHORESIS DEVICE

• US 20090287139A1
• Filed: 05/08/2009
• Published: 11/19/2009
• Est. Priority Date: 04/30/2004
• Status: Active Grant

• Current Assignee: EyeGate Pharma S.A.S. (Kiora Pharmaceuticals Incorporated)
• Original Assignee: EyeGate Pharma S.A.S. (Kiora Pharmaceuticals Incorporated)
• Inventors: Roy, Pierre
• Granted Patent: US 7,937,142 B2
• Time in Patent Office: Days
• US Class Current: 604/20
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61N 1/0412 Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
• CPC Class Codes: A61N 1/30 Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis

Abstract

The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.

Claims

1. An ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and including an active principle which is associated with an additive, such as a dendrimer, a polymers a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.

2-43. -43. (canceled)